73 research outputs found
Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature
The risk of developing lymphoma is greatly increased in HIV infection. Musculoskeletal manifestations of the human immunodeficiency virus (HIV) are common and are sometimes the initial presentation of the disease. Muscle, bone, and joints are involved by septic arthritis, myopathies and neoplasms. HIV-related neoplastic processes that affect the musculoskeletal system include Kaposi's sarcoma and non-Hodgkin's lymphoma, the latter being mainly localized at lower extremities, spine and skull
HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients
HIV-associated general immune activation is a strong predictor for HIV disease progression, suggesting that chronic immune activation may drive HIV pathogenesis. Consequently, immunomodulating agents may decelerate HIV disease progression. In an observational study, we determined immune activation in HIV patients receiving low-dose (5 mg/day) prednisolone with or without highly-active antiretroviral therapy (HAART) compared to patients without prednisolone treatment. Lymphocyte activation was determined by flow cytometry detecting expression of CD38 on CD8(+) T cells. The monocyte activation markers sCD14 and LPS binding protein (LBP) as well as inflammation markers soluble urokinase plasminogen activated receptor (suPAR) and sCD40L were determined from plasma by ELISA. CD38-expression on CD8+ T lymphocytes was significantly lower in prednisolone-treated patients compared to untreated patients (median 55.40% [percentile range 48.76-67.70] versus 73.34% [65.21-78.92], p = 0.0011, Mann-Whitney test). Similarly, we detected lower levels of sCD14 (3.6 μg/ml [2.78-5.12] vs. 6.11 μg/ml [4.58-7.70]; p = 0.0048), LBP (2.18 ng/ml [1.59-2.87] vs. 3.45 ng/ml [1.84-5.03]; p = 0.0386), suPAR antigen (2.17 μg/ml [1.65-2.81] vs. 2.56 μg/ml [2.24-4.26]; p = 0.0351) and a trend towards lower levels of sCD40L (2.70 pg/ml [1.90-4.00] vs. 3.60 pg/ml [2.95-5.30]; p = 0.0782). Viral load in both groups was similar (0.8 × 105 ng/ml [0.2-42.4 × 105] vs. 1.1 × 105 [0.5-12.2 × 105]; p = 0.3806). No effects attributable to prednisolone were observed when patients receiving HAART in combination with prednisolone were compared to patients who received HAART alone.\ud
Patients treated with low-dose prednisolone display significantly lower general immune activation than untreated patients. Further longitudinal studies are required to assess whether treatment with low-dose prednisolone translates into differences in HIV disease progression
Diagnosis of invasive candidiasis in the ICU
Invasive candidiasis ranges from 5 to 10 cases per 1,000 ICU admissions and represents 5% to 10% of all ICU-acquired infections, with an overall mortality comparable to that of severe sepsis/septic shock. A large majority of them are due to Candida albicans, but the proportion of strains with decreased sensitivity or resistance to fluconazole is increasingly reported. A high proportion of ICU patients become colonized, but only 5% to 30% of them develop an invasive infection. Progressive colonization and major abdominal surgery are common risk factors, but invasive candidiasis is difficult to predict and early diagnosis remains a major challenge. Indeed, blood cultures are positive in a minority of cases and often late in the course of infection. New nonculture-based laboratory techniques may contribute to early diagnosis and management of invasive candidiasis. Both serologic (mannan, antimannan, and betaglucan) and molecular (Candida-specific PCR in blood and serum) have been applied as serial screening procedures in high-risk patients. However, although reasonably sensitive and specific, these techniques are largely investigational and their clinical usefulness remains to be established. Identification of patients susceptible to benefit from empirical antifungal treatment remains challenging, but it is mandatory to avoid antifungal overuse in critically ill patients. Growing evidence suggests that monitoring the dynamic of Candida colonization in surgical patients and prediction rules based on combined risk factors may be used to identify ICU patients at high risk of invasive candidiasis susceptible to benefit from prophylaxis or preemptive antifungal treatment
CD4 cell count response to first-line combination ART in HIV-2+patients compared with HIV-1+patients: a multinational, multicohort European study
BACKGROUND: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL).
METHODS: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models.
RESULTS: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36–52) and 37 years (IQR 31–44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100–290) in HIV-2+ patients and 223 (95% CI 100–353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12 months were +105 (95% CI 77–134) in HIV-2+ patients and +202 (95% CI 199–205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5–44; P = 0.0127) in HIV-2+ patients compared with HIV-1+ patients.
CONCLUSIONS: A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2
Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies
Advancements in early diagnosis and the introduction of effective agents
have improved the rates of response of aspergillosis to primary
antifungal therapy. These changes allow the subsequent continuation of
cytotoxic chemotherapy and/or performance of hematopoietic stem cell
transplantation in an increasing number of patients with hematological
malignancies. These developments have increased interest in secondary
prophylaxis of aspergillosis, because the resumption of myelotoxic
chemotherapy in these patients is associated with high rates of relapse
of this opportunistic mycosis in the absence of prophylaxis. However,
the risk factors for relapsing invasive aspergillosis and the strategies
for reducing risk are not well defined. Furthermore, differentiating
aspergillosis relapse from reinfection with a new Aspergillus isolate is
problematic when using the available laboratory tools. We summarize the
existing knowledge regarding the pathogenesis of, risk factors for, and
natural history of relapsing invasive aspergillosis and review the
limited data regarding the role of secondary antifungal prophylaxis
Perspectives for the management of febrile neutropenic patients with cancer in the 21st century
Over the past several decades, there has been substantial progress in
the management of patients with febrile neutropenia. However, the
ever-changing patterns of infection, ecology, and antibiotic-resistance
trends do not allow the development of treatment guidelines that could
be applied universally. Hence, the institution’s predominant pathogens
and resistance patterns should guide the empirical choice of
antimicrobials. Prompt initiation of antimicrobial therapy remains the
gold standard. Monotherapy with the newer broad-spectrum antimicrobials
has tended to replace the classic combination therapy. Empirical
administration of glycopeptides, such as vancomycin, without
documentation of a gram-positive infection is not favored. The
development of risk-stratification models has allowed for identification
of low-risk patients with additional treatment options, such as early
discharge and exclusively outpatient treatment with oral antimicrobials.
The initiation of empirical antifungal therapy in persistently febrile
neutropenic patients has become common practice, especially recently,
since the introduction of new, effective, less toxic antifungal drugs.
It is hoped that the development of new nonculture-based diagnostic
methods will allow for the early detection of invasive fungal infections
and, thus, the replacement of empirical antifungal therapy with
pathogen-specific, preemptive therapy
- …